Evidence map›Paper›PMID 37568804›Full record

ReviewCancers2023

Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives.

Roberto Iezzi, Alessandro Posa, Andrea Contegiacomo, In Joon Lee, Reto Bale, Alessandro Tanzilli, Lorenzo Tenore, Felice Giuliante, Antonio Gasbarrini, Shraga Nahum Goldberg and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Roberto IezziDepartment of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.ORCID 0000-0002-2791-481X
Alessandro PosaDepartment of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.
Andrea ContegiacomoDepartment of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.
In Joon LeeDepartment of Radiology, National Cancer Center, Goyang 10408, Republic of Korea.
Reto BaleSection of Interventional Oncology-Microinvasive Therapy (SIP), Department of Radiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0003-0021-5792
Alessandro TanzilliDepartment of Radiology, Santa Maria Goretti Hospital, 04100 Latina, Italy.
Lorenzo TenoreDepartment of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.
Felice GiulianteSchool of Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Antonio GasbarriniSchool of Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Shraga Nahum GoldbergDivision of Image-Guided Therapy, Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel.ORCID 0000-0003-2940-9822
Tobias JakobsClinic of Interventional Radiology, Hospital Barmherzige Brueder, 93049 Munich, Germany.ORCID 0000-0001-7388-540X
Maurizio PompiliSchool of Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Irene BargelliniInstitute of Radiology, Candiolo Hospital, 10126 Turin, Italy.
Evis SalaDepartment of Diagnostic Imaging, Oncologic Radiotherapy and Hematology, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy.
Hyo-Cheol KimDepartment of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma represents an important cause of death worldwide. Early-stage hepatocellular carcinoma patients not suitable for surgery can be treated with a variety of minimally invasive locoregional interventional oncology techniques. Various guidelines in different countries address the treatment of hepatocellular carcinoma, but the actual treatment is usually discussed by a multidisciplinary tumor board in a personalized manner, leading to potential treatment differences based on Western and Eastern perspectives. The aim of this paper is to integrate literature evidence with the eminent experiences collected during a focused session at the Mediterranean Interventional Oncology (MIO) Live Congress 2023.

Indexed as

ablationchemoembolizationhepatocellular carcinomainterventional oncologylocoregional treatmentsradioembolization

Identifiers

PMID37568804
PMCPMC10416919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.